Candesartan Cilexetil

坎地沙坦西酯

Report date: 2022/03/30 13:41:47
NME

Base Information

Drug NameCandesartan Cilexetil
Drug Alias Name坎地沙坦西来替昔酯Candesartanumcandesartan坎地沙坦酯Tiadyl +[16] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAngiotensin II Receptor Type 1 antagonists
TargetsAngiotensin II Receptor Type 1
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Cognitive DysfunctionBipolar Disorder +[21] 
Global Approved IndicationsEssential HypertensionHypertensionHeart Failure
Approved Indications in ChinaHypertension
Original Approved Country/TerritoryUnited Kingdom
Original Approved Date1997/04/29
Country/TerritoryCzechiaBelgiumCanada +[21] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesEverest Medicines (China) Co LtdEverest Medicines LtdCheplapharm Arzneimittel Gmbh +[7] 
Inactive CompaniesAugusta UniversityThe University Of California DavisUniversity of Sydney +[14] 
Active IndicationsEssential HypertensionHypertensionHeart Failure +[4] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Cognitive DysfunctionBipolar Disorder +[17] 

Other Information

ATC CodeC09CA06
Related LinksWikipediaDrugBankKEGG